New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)

Fact Sheet

Project Information

**PAH-HOPE**

Grant agreement ID: 822258

Project website [ ]

**Funded under**

H2020-EU.3.
H2020-EU.2.3.
H2020-EU.2.1.

**Overall budget**

€ 3 570 000

**EU contribution**

€ 2 499 000

**Coordinated by**

ATXA THERAPEUTICS LTD

Ireland

Objective

ATXA Therapeutics Ltd is a company on a mission to offer new hope to patients with pulmonary arterial hypertension (PAH). PAH is a debilitating lung & heart disease with an urgent need for new medicines targeting different pathways than current drugs. These drugs do not effectively treat the disease, they carry serious side-effects, are poorly tolerated and only extend life-expectancy from 2.8 years (untreated) to 3.6 years (treated).

ATXA has developed novel therapeutic drugs to treat PAH. ATXA’s drug target is the human Thromboxane Receptor, a pathway involved in all the clinical features of PAH. Based on evaluations in 2 independent animal models of PAH, ATXA’s lead
NTP42 is predicted to be a truly disruptive disease-modifying drug, treating all aspects of PAH and greatly extending life expectancy. ATXA has completed the preclinical phase of its drug development program and has secured orphan designation from the EMA and FDA regulatory agencies for NTP42 for PAH treatment.

The objective of PAH-HOPE is to advance ATXA’s drug NTP42 into clinical development, starting from scaled up drug manufacture through to securing regulatory clinical trial authorization (CTA). Securement of CTA will position ATXA to advance NTP42 to Phase I-III clinical trials through to marketing authorization and product launch in 2025.

ATXA’s NTP42 fits with the current focus on value-based healthcare delivery, resulting in improved healthcare outcomes that matter to patients, physicians, payors but at lower cost of delivery. ATXA’s ambition is that NTP42 will capture 15% share of the lucrative PAH market resulting in $700m revenue within five years following global commercialization, growing to a mid-size SME with 155 employees. ATXA has 8 granted patents protecting NTP42 out to 2033 and beyond, which will address the imminent patent cliff of current PAH drugs. Moreover, ATXA’s NTP42 has platform applications in several other disease areas with blockbuster demand & market potential.

Fields of science

Programme(s)

Topic(s)

Call for proposal


Funding Scheme

SME-2 - SME instrument phase 2

Coordinator
<table>
<thead>
<tr>
<th>ATXA THERAPEUTICS LTD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Address</strong></td>
</tr>
<tr>
<td>Temple Chambers, 3</td>
</tr>
<tr>
<td>Burlington Road</td>
</tr>
<tr>
<td>D04 RD68 Dublin 4</td>
</tr>
<tr>
<td>Ireland</td>
</tr>
<tr>
<td><strong>Activity type</strong></td>
</tr>
<tr>
<td>Private for-profit entities</td>
</tr>
<tr>
<td>(excluding Higher or Secondary Education Establishments)</td>
</tr>
<tr>
<td><strong>EU contribution</strong></td>
</tr>
<tr>
<td>€ 2,499,000</td>
</tr>
</tbody>
</table>

**Last update:** 15 June 2021  
**Record number:** 217025

**Permalink:** [https://cordis.europa.eu/project/id/822258](https://cordis.europa.eu/project/id/822258)

© European Union, 2021